SCHEMBL3305724

SCHEMBL3305724

CC(C)(C)OC(=O)N1CCc2[nH]c3ccc(C(=O)N4CCc5ccccc5C4)cc3c2C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
PABPC1 P11940 1/20 0.50
ATM Q13315 1/20 0.50
HSP90AA1 P07900 2/20 0.49
HSP90AB1 P08238 2/20 0.49
MAPT P10636 2/20 0.48
POLB P06746 3/20 0.48
GAA P10253 1/20 0.48
ESR2 Q92731 1/20 0.47
NR1H2 P55055 1/20 0.47
CNR1 P21554 1/20 0.47
TRPV1 Q8NER1 1/20 0.46
PKM P14618 1/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
BAZ2B Q9UIF8 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3312381 0.84 LMNA (0.57) LMNASMN1; SMN2PABPC1ATMMAPT
SCHEMBL3312265 0.84 CNR1 (0.66) LMNASMN1; SMN2PABPC1ATMMAPT
SCHEMBL3310242 0.83 LMNA (0.50) LMNASMN1; SMN2PABPC1ATMMAPT
SCHEMBL61377 0.82 MEN1 (0.56) LMNASMN1; SMN2PABPC1ATMMAPT
SCHEMBL13329597 0.81 CNR1 (0.55) LMNASMN1; SMN2PABPC1ATMMAPT
SCHEMBL29357331 0.81 MAPT (0.69) LMNASMN1; SMN2PABPC1ATMMAPT
SCHEMBL2241936 0.81 MAPT (0.69) LMNASMN1; SMN2PABPC1ATMMAPT
SCHEMBL31117573 0.81 LMNA (0.55) LMNASMN1; SMN2PABPC1ATMMAPT
SCHEMBL3308539 0.80 MAPK1 (0.54) LMNASMN1; SMN2PABPC1ATMMAPT
SCHEMBL2832897 0.80 LMNA (0.76) LMNASMN1; SMN2PABPC1ATMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands ASTRAZENECA AB (SE) 2010-05-06 US disclosed
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands ASTRAZENECA AB (SE) 2010-05-06 US disclosed
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands ASTRAZENECA AB (SE) 2010-05-06 US disclosed
EP-1863810-A1 NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1' RECEPTOR LIGANDS AstraZeneca AB (SE) 2007-12-12 EP disclosed
WO-2006101434-A1 NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands CNR1, CNR2, OPRL1 LMNA 4434/4885SMN1; SMN2 1826/4885PABPC1 3222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.